Once-Daily Minoxidil Foam: What the Comparison With Solution Found

If a clinician has diagnosed female-pattern hair loss, choosing a minoxidil product involves concentration, formulation and application schedule. A trial comparing once-daily 5% foam with twice-daily 2% solution illustrates why similar average results do not automatically prove two regimens equivalent.

What the trial compared

Researchers randomized 322 women with female-pattern hair loss, 161 per group, to treatment for 52 weeks. The primary endpoint was change in target-area hair count at 24 weeks. This was 5% foam once daily versus 2% solution twice daily, not a comparison between two 5% products. [1]

Read the interval beside the average

The estimated foam-minus-solution difference was −0.3 hairs/cm², with a 95% confidence interval from −6.0 to 5.4. The lower limit crossed the trial's −5.0 hairs/cm² noninferiority boundary. That prevented the planned conclusion, even though the average difference was small. [1]

A noninferiority trial asks whether a treatment can be ruled out as worse than its comparator by a specified amount. FDA guidance explains the role of a chosen margin and confidence interval in that judgment. [4] Here, the interval crossed the boundary. The small average difference does not prove the regimens interchangeable, and a missed noninferiority criterion does not prove foam inferior.

The unit matters too: these were changes in hair counts within a measured scalp area. A difference of 0.3 hairs/cm² is not a 0.3% improvement, a change across the whole head or a prediction of how your part will look.

An earlier study reached a different conclusion

A 2011 trial randomized 113 women to the same concentrations and schedules for 24 weeks and reported noninferiority for target-area hair count and width. Participants rated foam more favorably for not interfering with styling. Local intolerance was less frequent with foam. Participants could distinguish the formulations, so they were not blinded. [2]

Keep the publication date and study population with each finding. A summary that cites only the earlier conclusion leaves out the later trial's missed criterion. Conversely, the later result does not erase the earlier findings about product acceptability. Ask your clinician how effectiveness, irritation and the schedule you can follow affect the choice.

Use the instructions for the product in your hand

The cited US women's 5% foam label directs half a capful once daily onto the scalp in the hair-loss area, followed by handwashing. More product or more frequent use will not improve results. Its leaflet advises leaving it on the scalp for about four hours before washing. Continued use is needed to maintain regrowth. [3]

Bring the actual carton or a photograph to the discussion. Record the concentration, foam or solution, directions and any other scalp treatments. Do not transfer one product's schedule to another because both contain minoxidil.

New shedding still needs a diagnosis

The foam label says not to use it for sudden or patchy loss, an unknown cause, or an irritated or painful scalp. It warns about use during pregnancy or breastfeeding. Stop and ask a doctor for chest pain, rapid heartbeat, faintness, dizziness, swelling, scalp irritation or no regrowth after six months. These are selected warnings; read the complete label. [3]

The comparison trials concerned female-pattern loss. They do not establish a treatment for every episode of shedding during GLP-1 treatment. Start with the diagnosis and minoxidil guide if the cause has not been assessed.

For a separate route-of-treatment comparison, see the oral versus topical minoxidil trial review.

Printed book

How to Keep Your Face on GLP-1

$12.95 + free shipping

Order Now

✓ 30 day money back guarantee

This article provides general education, not a diagnosis or an individual treatment plan. Medication information refers to US sources. Discuss medication, nutrition and cosmetic treatment decisions with qualified clinicians.